Safety and feasibility of targeted agent combinations in solid tumours.
about
The steady progress of targeted therapies, promising advances for lung cancerActivating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeTargeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.Targeting bacterial adherence inhibits multidrug-resistant Pseudomonas aeruginosa infection following burn injuryAdaptive designs for dual-agent phase I dose-escalation studies.Phase 1 trial design: is 3 + 3 the best?Translational research in oncology--10 years of progress and future prospects.Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.Combine and conquer: challenges for targeted therapy combinations in early phase trials.Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein BiomarkersStructural and Functional View of Polypharmacology.Intratumor heterogeneity: origins, clinical significance and optimal strategies for cancer treatment.Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.A Convergence-Based Framework for Cancer Drug Resistance.Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance
P2860
Q26746895-E911B6FB-AC27-4A95-877A-02132156EB4EQ27852954-A807B65B-AEC3-4B19-94F1-942F98304DC5Q34056295-99EC1EFE-72D9-4601-B03C-03796451DA96Q36820882-DEFA689A-F3EA-4C13-B809-E3DA9FD8E164Q37268981-BD6539F4-3792-44A9-92CA-C19AC2170114Q37518925-3A138027-79DB-4D0D-BB0B-2A30A5F5ED1DQ38090897-079163E3-44F6-4EDD-97B6-B0D8850E4615Q38222466-E2099D7E-2D88-4A15-95AD-0DCA241FBB0EQ38257126-106C174E-033F-4B18-AE82-AADC70F2F92DQ38262501-4DCB9866-A207-4CEE-8318-7D553068E0DBQ38734451-A2D9BB04-A41A-4A82-87D9-6E5432D79D50Q38847931-6B7EB0BF-A9CF-4C88-9F7E-590222BB3E79Q41580357-5ACEED60-9B21-4CF7-8529-0F771B3EA563Q48596032-2F458834-8C3A-4299-ACC3-05594F1A0B61Q53259976-36BEE16A-3DCB-4E98-AA80-D491D3665ECFQ53682041-5449CAA7-81B9-4406-930E-F3A925875E36Q58802587-1ACC9275-9F15-423F-A8F5-41C10D3D5E66
P2860
Safety and feasibility of targeted agent combinations in solid tumours.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Safety and feasibility of targeted agent combinations in solid tumours.
@en
type
label
Safety and feasibility of targeted agent combinations in solid tumours.
@en
prefLabel
Safety and feasibility of targeted agent combinations in solid tumours.
@en
P2093
P2860
P1476
Safety and feasibility of targeted agent combinations in solid tumours.
@en
P2093
James H Doroshow
Myrtle Davis
Shivaani Kummar
Sook Ryun Park
P2860
P304
P356
10.1038/NRCLINONC.2012.245
P407
P577
2013-01-29T00:00:00Z